<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04921657</url>
  </required_header>
  <id_info>
    <org_study_id>GWAS</org_study_id>
    <nct_id>NCT04921657</nct_id>
  </id_info>
  <brief_title>Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin</brief_title>
  <official_title>Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of the Two Commonly Used Statins, Simvastatin and Rosuvastatin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will perform a genome-wide association study (GWAS) of the lipid responses to&#xD;
      rosuvastatin and simvastatin and plasma concentrations of these two statins in a homogeneous&#xD;
      group of Han Chinese patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A GWAS will be performed on about 360 Han Chinese patients with hypercholesterolaemia (which&#xD;
      may be familial or non-familial) who have previously participated in a research project on&#xD;
      the pharmacogenetics of statins and who have been treated with rosuvastatin and simvastatin&#xD;
      to determine the genetic factors that may be related to the reduction in plasma low-density&#xD;
      lipoprotein cholesterol (LDL-C) and plasma concentrations of these two statins. The lipid&#xD;
      profiles were measured at baseline on no lipid-lowering treatment and after 4-6 week&#xD;
      treatment of rosuvastatin 10 mg daily and after treatment with simvastatin 40 mg daily for at&#xD;
      least 6 weeks with at least a 4-week washout period between the two treatments. Plasma&#xD;
      concentrations of these two statins and their active metabolites about 12 hours after&#xD;
      administration of statins have been measured by liquid chromatography-tandem mass&#xD;
      spectrometry (LC-MS/MS).&#xD;
&#xD;
      Genotyping for the whole-genome scan will be carried out on the Illumina OminiExpress&#xD;
      beadchip (Illumina, San Diego, CA). The samples will be processed using the Illumina iScan&#xD;
      platform at the Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong&#xD;
      (CUHK).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2021</completion_date>
  <primary_completion_date type="Actual">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genome-wide analysis of DNA sample</measure>
    <time_frame>DNA samples taken after 4 weeks on statin treatment.</time_frame>
    <description>Presence or absence of single-nucleotide polymorphisms (SNPs) at over 700,000 points on the DNA samples will be analyzed using a whole-genome scan with the Illumina Omini Express BeadChip to identify which of these SNPs are associated with the LDL cholesterol reduction with rosuvastatin.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">362</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Patients treated with statin.</arm_group_label>
    <description>Patients with hypercholesterolemia treated with rosuvastatin 10 mg daily or simvastatin 40 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <arm_group_label>Patients treated with statin.</arm_group_label>
    <other_name>Simvastatin 40 mg</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypercholesterolemia attending medical clinics in Hong Kong who were eligible&#xD;
        for statin treatment according to local guidelines in Hong Kong and willing to give&#xD;
        informed consent for DNA analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of hypercholesterolemia (familial or non-familial)&#xD;
&#xD;
          -  Eligible for statin treatment according to local guidelines in the Hong Kong Public&#xD;
             Hospital system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking other medication which may interact with the pharmacokinetics or lipid response&#xD;
             to statins.&#xD;
&#xD;
          -  Not willing to cooperate with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BRIAN TOMLINSON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brian Tomlinson</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Brian Tomlinson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Statins</keyword>
  <keyword>Pharmacogenomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

